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Biological Screening
Antagonist Activity Assay CHO-K1/5-HT 2B cell line was obtained from GenScript and used for cellular screening of the compounds. CHO-K1 cells expressing 5-HT 2B were seeded in a 384-well black-wall, clear-bottom plate at a density of 20,000 cells per well in 20 μL of growth medium (10% FBS + 90% F12), 18 h prior to the experiment and maintained at 37 ℃/5% CO 2 . 20 μL of dye-loading solution and 10 μL of tested compound solution (at concentrations five times to the final assay concentrations) were added into the well. Then the plate was placed into a 37 °C incubator for 60 min, followed by 15 min at room temperature. At last, 12.5 μL of control agonist (at concentrations five times to the EC80 concentrations) was added. The control agonist was added to reading plate at 20 s and the fluorescence signal was monitored for an additional 100 s. The cells stimulated with assay buffer (HBSS-HEPES) containing 0.1% DMSO were chosen as background; cells stimulated with 12 nM (EC80 of the cell line) of 5-HT were chosen as the agonist control; cell treated with SB206553 were chosen as positive control of the screening.
The baseline reading was specified as the average fluorescent intensity value during 1s to 20 s. The relative fluorescent units (ΔRFU) intensity values were calculated with the maximal fluorescent units (21 s to 120 s) subtracting the average value of baseline reading. The % inhibition of the tested compound was calculated from the following equation:
Binding Assay
The experimental binding assays were performed following the standard protocol. 1 H]LY278584 for 5-HT 3 ) were used in the K i determination assays. The radio-labeled reference compounds are diluted to 5X final assay concentration (50 μM for a final assay concentration of 10 μM) in the standard binding buffer. Subsequently, 50 μL aliquots of buffer (negative control), test compound, and reference compound are added in quadruplicate to the wells of a 96-well plate, each of which contains 50 μL of 5X radioligand and 100 μL of buffer. Finally, receptor-containing, crude membrane fractions are resuspended in an appropriate volume of buffer and dispensed (50 μL per well) into the 96-well plate. Radioligand binding is allowed to equilibrate (typically for 1.5 hours at room temperature), and then bound radioactivity is isolated by filtration onto 0.3% polyethyleneimine-treated, 96-well filter mats using a 96-well Filtermate harverster. The radioactivity retained on the filters is counted in a Microbeta scintillation counter. Total bound radioactivity is estimated from quadruplicate wells without containing test or reference compound and adjusted to 100%; non-specifically bound radioactivity is assessed from quadruplicate wells containing 10 μM of a suitable reference compound and adjusted to 0%. The average bound radioactivity in the presence of the test compound (10 μM final assay concentration, quadruplicate determinations) is expressed on the percent scale. The percent inhibition of radioligand binding is calculated as follows: %inhibition = 100% -% radioactivity-bound.
Pharmacokinetic Profiling
 Stability in simulated fluids (t 1/2 , min) was evaluated using erythromycin as a reference compound. 2 Stability in simulated fluids (t 1/2 , min) 
